SCHEMBL17810261

SCHEMBL17810261

Cc1cnc(-c2cn(C)nc2C(F)(F)F)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
PRKDC P78527 1/20 0.41
BRD4 O60885 2/20 0.40
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TGFBR1 P36897 1/20 0.38
FGFR1 P11362 2/20 0.38
FGFR2 P21802 2/20 0.38
FGFR3 P22607 2/20 0.38
MBOAT4 Q96T53 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CREBBP Q92793 1/20 0.36
CSNK1D P48730 2/20 0.35
MAPK14 Q16539 2/20 0.35
PDE10A Q9Y233 1/20 0.35
IDH1 O75874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17806745 0.83 CYP2C19 (0.39) CYP2C19CYP3A4PRKDCBRD4ALDH1A1
SCHEMBL17794789 0.78 CYP2C19 (0.46) CYP2C19CYP3A4BRD4ALDH1A1L3MBTL1
SCHEMBL17809689 0.77 CYP2C19 (0.45) CYP2C19CYP3A4PRKDCBRD4ALDH1A1
SCHEMBL17795432 0.75 PRMT5 (0.47) CYP2C19CYP3A4BRD4ALDH1A1L3MBTL1
SCHEMBL21051429 0.72 BRD4 (0.45) CYP2C19CYP3A4BRD4ALDH1A1L3MBTL1
SCHEMBL17785580 0.72 BRD4 (0.45) CYP2C19CYP3A4BRD4ALDH1A1L3MBTL1
SCHEMBL17806490 0.71 BRD4 (0.42) CYP2C19CYP3A4BRD4ALDH1A1L3MBTL1
SCHEMBL17809695 0.71 BRD4 (0.43) CYP2C19CYP3A4BRD4ALDH1A1L3MBTL1
SCHEMBL16479495 0.69 S1PR2 (0.45) CYP2C19CYP3A4PRKDCBRD4ALDH1A1
SCHEMBL3329152 0.69 CYP2C19 (0.43) CYP2C19CYP3A4BRD4ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP2C19 3069/4885CYP3A4 3799/4885PRKDC 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.